Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
23.5 ^USD	+3.12%		-2.61%	+130.62%

01/06	Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib	CI
15/05	Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Cullinan Therapeutics, Inc. Announces Board Changes

May 16, 2024 at 01:35 am IST

Cullinan Therapeutics, Inc. announced that David Meek has been appointed to the Board of Directors, effective May 15, 2024. Mr. Meek most recently served as CEO and board member of Mirati Therapeutics, Inc, and previously as CEO and board member of FerGene, Inc. and Ipsen. Thomas Ebeling will resign from Cullinan?s Board of Directors at the end of his term on June 26, 2024.

Latest news about Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib	01/06	CI
Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Cullinan Therapeutics, Inc. Announces Board Changes	16/05	CI
Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing	09/05	MT
Cullinan Therapeutics, Inc. announced that it has received $280.000024 million in funding from a group of investors	30/04	CI
Cullinan Therapeutics Appoints Mary Kay Fenton as CFO	30/04	MT
Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer	29/04	CI
Transcript : Cullinan Oncology, Inc. - Special Call	16/04
Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases	16/04	CI
Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding from a group of investors	15/04	CI
Cullinan Oncology, Inc.(NasdaqGS:CGEM) added to S&P Biotechnology Select Industry Index	18/03	CI
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave	14/03	MT
Cullinan Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024	14/03	CI
Cullinan Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03	CI
North American Morning Briefing : Stock Futures -2-	13/03	DJ
Cullinan Oncology Secures FDA Approval for CLN-619's Investigational New Drug Application in Multiple Myeloma	01/03	MT
Cullinan Oncology Insider Sold Shares Worth $647,200, According to a Recent SEC Filing	05/02	MT
Cullinan Oncology Insider Sold Shares Worth $563,600, According to a Recent SEC Filing	31/01	MT
Transcript : Cullinan Oncology, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM	12/01
Cullinan Oncology Doses First Patient in Study of Advanced Solid Tumor Treatment Candidate	15/12	MT
Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines	15/12	CI
Cullinan Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023	03/11	CI
Transcript : Cullinan Oncology, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 10:50 AM	13/23/13

Chart Cullinan Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.

Sector

Biotechnology & Medical Research

Calendar

26/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.5 USD

Average target price

33 USD

Spread / Average Target

+40.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CULLINAN THERAPEUTICS, INC.	+130.62%	135.44Cr
MODERNA, INC.	+43.36%	5.46TCr
IQVIA HOLDINGS INC.	-5.31%	3.99TCr
LONZA GROUP AG	+37.52%	3.88TCr
ICON PUBLIC LIMITED COMPANY	+14.75%	2.69TCr
CELLTRION, INC.	-12.56%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	1.88TCr
UNITED THERAPEUTICS CORPORATION	+25.12%	1.22TCr
BIO-TECHNE CORPORATION	+0.04%	1.22TCr
MEDPACE HOLDINGS, INC.	+26.04%	1.19TCr

Other Biotechnology & Medical Research